References
- Buckwalter J. A., Saltzman C., Brown T., Schurman D. J. The impact of osteoarthritis: implications for research. Clin Orthop 2004; S6–15
- van den Berg W. B., van der Kraan P. M., Scharstuhl A., van Beuningen H. M. Growth factors and cartilage repair. Clin Orthop Relat Res 2001; S244–50
- Vergunst C. E., van de Sande M. G., Lebre M. C., Tak P. P. The role of chemokines in rheumatoid arthritis and osteoarthritis. Scand J Rheumatol 2005; 34: 415–25
- Moos V., Rudwaleit M., Herzog V., Hohlig K., Sieper J., Muller B. Association of genotypes affecting the expression of interleukin‐1beta or interleukin‐1 receptor antagonist with osteoarthritis. Arthritis Rheum 2000; 43: 2417–22
- Muller B. Cytokine imbalance in non‐immunological chronic disease. Cytokine 2002; 18: 334–9
- Sanchez C., Deberg M. A., Piccardi N., Msika P., Reginster J. Y., Henrotin Y. E. Osteoblasts from the sclerotic subchondral bone downregulate aggrecan but upregulate metalloproteinases expression by chondrocytes. This effect is mimicked by interleukin‐6, ‐1β and oncostatin M pre‐treated non‐sclerotic osteoblasts. Osteoarthritis Cartilage 2005; 13: 979–87
- Jikko A., Wakisaka T., Iwamoto M., Hiranuma H., Kato Y., Maeda T., Fujishita M., et al. Effects of interleukin‐6 on proliferation and proteoglycan metabolism in articular chondrocyte cultures. Cell Biol Int 1998; 22: 615–21
- Kawano M., Hirano T., Matsuda T., Taga T., Horii Y., Iwato K., Asaoku H., et al. Autocrine generation and requirement of BSF‐2/IL‐6 for human multiple myelomas. Nature 1988; 332: 83–5
- Reddy S. V. Regulatory mechanisms operative in osteoclasts. Crit Rev Eukaryot Gene Expr 2004; 14: 255–70
- Muller‐Steinhardt M., Hartel C., Muller B., Kirchner H., Fricke L. The interleukin‐6 −174 promoter polymorphism is associated with long‐term kidney allograft survival. Kidney Int 2002; 62: 1824–7
- Kaneko S., Satoh T., Chiba J., Ju C., Inoue K., Kagawa J. Interleukin‐6 and interleukin‐8 levels in serum and synovial fluid of patients with osteoarthritis. Cytokines Cell Mol Ther 2000; 6: 71–9
- Massicotte F., Lajeunesse D., Benderdour M., Pelletier J. ‐P., Hilal G., Duval N., et al. Can altered production of interleukin‐1beta, interleukin‐6, transforming growth factor‐beta and prostaglandin E2 by isolated human subchondral osteoblasts identify two subgroups of osteoarthritic patients?. Osteoarthritis Cartilage 2002; 10: 491–500
- Fishman D., Faulds G., Jeffery R., Mohamed‐Ali V., Yudkin J. S., Humphries S., et al. The effect of novel polymorphisms in the interleukin‐6 (IL‐6) gene on IL‐6 transcription and plasma IL‐6 levels, and an association with systemic‐onset juvenile chronic arthritis. J Clin Invest 1998; 102: 1369–76
- Pola E., Papaleo P., Pola R., Gaetani E., Tamburelli F. C., Aulisa L., Logroscino C. A. Interleukin‐6 gene polymorphism and risk of osteoarthritis of the hip: a case–control study. Osteoarthritis Cartilage 2005; 13: 1025–8
- Yokota S., Miyamae T., Imagawa T., Iwata N., Katakura S., Mori M., et al. Therapeutic efficacy of humanized recombinant anti‐interleukin‐6 receptor antibody in children with systemic‐onset juvenile idiopathic arthritis. Arthritis Rheum 2005; 52: 818–25